Clinical trials: Gastric Cancer, completed
Diagnosis, Gastric Cancer
PWP1's Expression in Gastric Cancer.
Background：Gastric cancer is a globally important disease and the fifth most diagnosed malignant cancer in the world. Because it is usually diagnosed at an advanced stage, gastric cancer has a high mortality rate, making it the…
- Trial name
- NCT06392750
- Testing
- Collection of tumor tissue specimens
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Northern Jiangsu People's Hospital
Advanced Solid Tumor, Cholangiocarcinoma
Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors
This is a Phase Ib/II, multicenter, open-label study to evaluate the safety and preliminary efficacy of TT-00420 tablet, as monotherapy or in combination regimens, in patients with advanced solid tumors.
- Conditions
- Advanced Solid Tumor, Cholangiocarcinoma, HER2-negative Breast Cancer, Triple Negative Breast Cancer
- Trial name
- NCT04742959
- Testing
- TT-00420, Nab-Paclitaxel
- Where
- 6 sites in United States
- Volunteers
- 203 people
- Sponsor
- TransThera Sciences (Nanjing), Inc.
HER2-positive Breast Cancer, HER2-positive Gastric Cancer
PRS-343 in HER2-Positive Solid Tumors
A multi center, open-label, Phase 1 dose escalation study with expansion cohort is designed to determine the MTD, RP2D and dosing schedule of PRS-343 in patients with HER2+ advanced or metastatic solid tumors.
- Conditions
- HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2-positive Bladder Cancer, HER2-positive Solid Tumor
- Trial name
- NCT03330561
- Testing
- PRS-343
- Where
- 10 sites in United States
- Volunteers
- 85 people
- Sponsor
- Pieris Pharmaceuticals, Inc.
HER2-positive Breast Cancer, HER2-positive Gastric Cancer
PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors
A Phase 1b, open-label, dose escalation study of PRS-343 in combination with atezolizumab in patients with HER2-positive advanced or metastatic solid tumors.
- Conditions
- HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2-positive Bladder Cancer, HER2-positive Solid Tumor
- Trial name
- NCT03650348
- Testing
- PRS-343 in Combination with Atezolizumab
- Where
- 8 sites in United States
- Volunteers
- 41 people
- Sponsor
- Pieris Pharmaceuticals, Inc.
Advanced Gastric Cancer, Neoadjuvant Therapy
Neoadjuvant Treatment Based on Gastric Cancer Molecular Subtyping.
Extensive research employing diverse omics methodologies has unveiled a varied landscape of gastric cancer (GC). Recent progress in next-generation sequencing and other genomic technologies has facilitated a more intricate…
- Conditions
- Advanced Gastric Cancer, Neoadjuvant Therapy, Multi-omics Analysis
- Trial name
- NCT06376773
- Testing
- combination chemotherapy with Apatinib or Camrelizumab
- Where
- China
- Volunteers
- 234 people
- Sponsor
- Fujian Medical University
Gastric Cancer
Neo-Sequence 1: Neoadjuvant Chemotherapy With or Without Antiangiogenesis and Sequential Immunotherapy for HER2-negative MMR-proficient Locally Advanced Gastric or Gastroesophageal Adenocarcinoma
This is a single-institution, prospective phase II trial designed to evaluate the efficacy of neoadjuvant chemotherapy and sequential immunotherapy in patients with locally advanced esophagogastric junction and gastric…
- Trial name
- NCT05540145
- Testing
- SOX plus Paclitaxel with or without antiangiogenesis followed by PD-1 antibody
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Gastric Cancer
ERAS for Gastric Cancer Patients After NACT
Background: Gastric cancer patients receiving neoadjuvant chemotherapy (NACT) are more vulnerable to perioperative stress. Enhanced recovery after surgery (ERAS) is widely used in surgical patients aiming at reducing stress…
- Trial name
- NCT06365814
- Testing
- enhanced recovery after surgery, conventional perioperative management
- Where
- China
- Volunteers
- 252 people
- Sponsor
- The Affiliated Hospital of Qingdao University
Gastric Cancer, Preneoplastic Condition
BLI for the Diagnosis of Precancerous Conditions
Introduction: Traditionally, White Light Endoscopy (WLE), enhanced by biopsies following the updated Sydney system guidelines, has been the benchmark for diagnosing and classifying gastric preneoplastic conditions.
- Conditions
- Gastric Cancer, Preneoplastic Condition, Early Gastric Cancer
- Trial name
- NCT04768218
- Where
- Portugal
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- Instituto Portugues de Oncologia, Francisco Gentil, Porto
Gastric Cancer
A Novel Online Calculator to Predict Long-term Survival and Recurrence Risk of Patients With Gastric Adenocarcinoma
This study aimed to develop a novel Prognostic Oxidative Stress-Immune-Inflammatory Score (POSII Score) and introduce an innovative online calculator designed to predict long-term survival and assess the recurrence risk of…
- Trial name
- NCT06337266
- Where
- China
- Volunteers
- 3,622 people
- Sponsor
- Fujian Medical University
Gastric Cancer
Systemic Oxidative Stress Score as a Predictor of Gastric Cancer Survival and Recurrence Risk
The Systemic Oxidative Stress Score (SOSS) , a comprehensive score reflecting the oxidative stress conditions in the microenvironment, can independently and effectively predict tumor burden and long-term prognosis in GC patients.
- Trial name
- NCT06337279
- Where
- China
- Volunteers
- 3,820 people
- Sponsor
- Fujian Medical University
Melanoma, Non-small Cell Lung Cancer
A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies
This is a study to determine the maximum tolerated dose (MTD) for CDX-1140 (CD40 antibody), either alone or in combination with CDX-301 (FLT3L), pembrolizumab, or chemotherapy and to further evaluate its tolerability and efficacy…
- Conditions
- Melanoma, Non-small Cell Lung Cancer, Breast Cancer, Gastric Cancer
- Trial name
- NCT03329950
- Testing
- CDX-1140, CDX-301, pembrolizumab
- Where
- 11 sites in United States
- Volunteers
- 132 people
- Sponsor
- Celldex Therapeutics
GastroEsophageal Cancer, Gastric Cancer
A Phase II a Study of Lenvatinib, a Multi-targeted Tyrosine Kinase Inhibitor, Combined With Pembrolizumab (PD-1 Inhibitor) for the Treatment of Metastatic Gastroesophageal Cancer Patients Who Have Progressed on First or Subsequent Line Therapies
This is an open label, single arm phase II study, to determine the overall response rate for the combination of lenvatinib and pemrolizumab in patients with metastatic gastroesophageal cancer who have progressed on first or…
- Trial name
- NCT03321630
- Testing
- Lenvatinib, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- NYU Langone Health
Oesophageal Cancer, Gastric Cancer
Google Location History Following Oesophagectomy and/or Gastrectomy
Surgery is the mainstay of treatment for patients with early-disease esophageal and gastric cancer. Open surgery for oesophageal cancer commonly involves large incisions in the chest, which is associated with a high rate of…
- Conditions
- Oesophageal Cancer, Gastric Cancer, Survivorship, Quality of Life
- Trial name
- NCT05035602
- Testing
- Physical activity assessment
- Where
- United Kingdom
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Gastric Cancer, Bone Marrow Metastasis
Infusional Fluorouracil and Weekly Docetaxel for Gastric Cancer With Bone Marrow Involvement and DIC
A distinctive subtype of gastric adenocarcinoma with extensive bone marrow metastasis and DIC has been described. Few patients have been treated properly due to the lack of standard care.
- Conditions
- Gastric Cancer, Bone Marrow Metastasis, Disseminated Intravascular Coagulation
- Trial name
- NCT04547153
- Testing
- 5-fluorouracil, Docetaxel
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Gastric Cancer
Efficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer.
This study is a phase III, multi-centre study of olaparib in combination with paclitaxel, compared with placebo in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line…
- Trial name
- NCT01924533
- Testing
- Olaparib, Paclitaxel
- Where
- 57 sites in China, Japan and 2 more
- Volunteers
- 525 people
- Sponsor
- AstraZeneca
Hypoxia, Gastric Cancer
Capnographic Monitoring in Gastrointestinal Endoscopy for Elderly Patients
Hypoxia is the most common adverse event in gastrointestinal endoscopes sedated with propofol and sufentanil, especially in elderly people.
- Conditions
- Hypoxia, Gastric Cancer, Gastric Polyp, Colon Polyp
- Trial name
- CapnoGI (NCT05030870)
- Testing
- Capnography monitoring, Standard monitoring
- Where
- 3 sites in China
- Volunteers
- 1,800 people, healthy volunteers welcome
- Sponsor
- RenJi Hospital
Early Gastric Cancer
A Clinical Trial to Evaluate the Sensitivity and Specificity of "WAYMED Endo" Compared to the Endoscopists in Classifying Early Gastric Cancer (EGC) Based on the Depth of Invasion in Endoscopic Images
The purpose of this clinical trial is to prove that the prediction capability of 'WAYMED endo' is superior to that of the endoscopists in classifying EGC based on the depth of invasion categories in gastro-endoscopic images.
- Trial name
- NCT06317103
- Testing
- WADYMED endo, Control group (the endoscopists)
- Where
- South Korea
- Volunteers
- 653 people
- Sponsor
- WAYCEN Inc
Gastric Cancer, Esophagus Cancer
KeyLargo: Pembrolizumab + Oxaliplatin + Capecitabine in Gastric Cancer
This study will be conducted in two stages: 1) safety validation and 2) dose expansion 1. Safety Validation Cohort: The first portion of the study will preliminarily establish the tolerability of the combination of pembrolizumab…
- Trial name
- NCT03342937
- Testing
- Oxaliplatin+Capecitabine+Pembrolizumab
- Where
- 7 sites in United States
- Volunteers
- 36 people
- Sponsor
- Duke University
Gastric Cancer
Cost-minimization Analysis of Gastric Cancer Treatments in Hong Kong
This is a retrospective cost-minimization analysis study to compare the costs of treatment with EOF vs EOX regimens in patients with gastric cancer (GC) in Hong Kong.
- Trial name
- NCT01679054
- Where
- Hong Kong
- Volunteers
- 58 people
- Sponsor
- Vivian Wing Yan Lee
Breast Cancer, Gastric Cancer
Trial of KN026 in Patients With HER2-positive Advanced Malignant Breast Cancer and Gastric Cancer
This is a first-in-human (FIH), open-label, phase 1 dose-escalation study of KN026 in subjects with HER2 positive advanced breast and Gastric Cancer. The standard "3 + 3" design was used for dose escalation.
- Trial name
- NCT03619681
- Testing
- KN026
- Where
- China
- Volunteers
- 63 people
- Sponsor
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd